<DOC>
	<DOCNO>NCT00003870</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill cancer cell . PURPOSE : Phase II trial study effectiveness monoclonal antibody therapy , cyclophosphamide , total-body irradiation follow peripheral stem cell transplantation treat patient advanced recurrent acute lymphocytic leukemia .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy , Cyclophosphamide , Total-Body Irradiation Followed Peripheral Stem Cell Transplantation Treating Patients With Advanced Recurrent Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I. Assess efficacy toxicity iodine I 131 monoclonal antibody BC8 , cyclophosphamide , total body irradiation patient advance acute lymphocytic leukemia receive HLA match related unrelated bone marrow transplantation . II . Determine maximum tolerate dose ( MTD ) iodine I 131 monoclonal antibody BC8 patient . III . Estimate MTD radiation deliver iodine I 131 monoclonal antibody BC8 marrow . IV . Study influence marrow cellularity , level antigen expression leukemic cell , degree antigen saturation antibody biodistribution iodine I 131 monoclonal antibody BC8 patient . OUTLINE : This dose-escalation study . All patient receive test dose iodine I 131 monoclonal antibody BC8 ( MOAB BC8 ) IV several hour 6-14 day prior therapeutic dose . Patients receive therapeutic dose iodine I 131 MOAB BC8 IV several hour day -11 , total body irradiation 30-40 minute twice day day -6 -4 , cyclophosphamide IV 1 hour day -3 -2 . Patients undergo allogenic bone marrow transplantation day 0 . Patients receive intrathecal methotrexate twice prior transplantation every week 4 week begin day 32 posttransplant . Cohorts 4 patient receive escalate dos iodine I 131 monoclonal antibody maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 4 patient experience dose-limiting toxicity . Patients follow first 100 day , 6 , 9 12 month , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 40 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute lymphocytic leukemia beyond first remission refractory Relapsed disease must CD45 positive Patients remission may CD45 negative PATIENT CHARACTERISTICS : Age : 2 55 Performance status : Not specify Life expectancy : More 60 day Hematopoietic : Circulating blast count le 10,000/mm3 ( control hydroxyurea similar agent allow ) Hepatic : Bilirubin le 1.5 mg/dL AST le 1.5 time upper limit normal ( ULN ) Must venoocclusive liver disease Renal : Creatinine le 2.0 mg/dL OR le 1.5 time ULN age Other : No active infection HIV negative No circulating antimouse immunoglobulin antibody Must able tolerate diagnostic therapeutic procedure ( e.g. , radiation isolation ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy maximum tolerated level normal organ Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
</DOC>